Article

Alcon, Advanced Medical Optics enter into IOL patent agreement

Huenenberg, Switzerland-Alcon Inc. and Advanced Medical Optics (AMO) have entered into a patent cross-licensing agreement relating to a specified one-piece IOL design and lubricious coatings for IOL insertion devices.

Huenenberg, Switzerland-Alcon Inc. and Advanced Medical Optics (AMO) have entered into a patent cross-licensing agreement relating to a specified one-piece IOL design and lubricious coatings for IOL insertion devices.

The agreement provides AMO with paid-up, non-exclusive, worldwide licenses restricted to single-piece IOLs having the same design as AMO’s recently launched IOL (Tecnis), according to a prepared statement issued by Alcon. The licenses assure AMO of freedom to operate with respect to the subject Alcon patents, relative to the launched IOL and any future IOL models having the same design platform. AMO will pay Alcon a lump sum of $10 million for those licenses, according to Alcon.

Additionally, Alcon will receive paid-up, non-exclusive, worldwide licenses under two families of patents owned by AMO, according to the statement. The licenses assure Alcon of freedom to operate with respect to the two patents, relative to the coating systems currently used in its IOL insertion devices (Monarch and AcrySert), as well as any future coating systems of a similar type that Alcon may develop. In the statement, Alcon said it will pay AMO a lump sum of $31 million for those licenses.

Other terms of the agreement were not disclosed.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.